Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications
2011

Study of Anti-Malarial Drug Resistance in Yemen

Sample size: 124 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mubjer Reem A, Adeel Ahmed A, Chance Michael L, Hassan Amir A

Primary Institution: Aden University, Yemen

Hypothesis

What are the molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen?

Conclusion

The study provides baseline data on anti-malarial drug resistance markers in Yemen, indicating high prevalence of certain mutations but poor predictive value for treatment failure.

Supporting Evidence

  • 61% of patients experienced treatment failure after 14 days.
  • 98% of pre-treatment samples showed the pfcrt T76 mutation.
  • 5% of samples had the dhfr Arg-59 mutation, indicating emerging resistance.

Takeaway

This study looked at how well a malaria treatment works in Yemen and found that many patients didn't get better, even though the drug was supposed to help.

Methodology

The study involved a therapeutic efficacy test of chloroquine in 124 patients and molecular analysis of blood samples for resistance markers.

Potential Biases

Potential bias due to the selection of patients who sought treatment at a specific hospital.

Limitations

The study was limited to a specific geographic area and may not represent broader trends in Yemen.

Participant Demographics

Patients aged 1 to 40 years, median age 9.5 years.

Statistical Information

P-Value

0.000

Confidence Interval

95% CI = 52.7-70.9

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1475-2875-10-245

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication